Chronic T cell proliferation in brains after stroke could interfere with the efficacy of immunotherapies by Heindl, S. et al.
BRIEF DEFINITIVE REPORT
Chronic T cell proliferation in brains after stroke
could interfere with the efficacy of immunotherapies
Steffanie Heindl1, Alessio Ricci1, Olga Carofiglio1, Qihui Zhou2, Thomas Arzberger3,4, Nikolett Lenart5, Nicolai Franzmeier1,
Tibor Hortobagyi6, Peter T. Nelson7, Ann M. Stowe7, Adam Denes5, Dieter Edbauer2,8, and Arthur Liesz1,8
Neuroinflammation is an emerging focus of translational stroke research. Preclinical studies have demonstrated a critical role
for brain-invading lymphocytes in post-stroke pathophysiology. Reducing cerebral lymphocyte invasion by anti-CD49d
antibodies consistently improves outcome in the acute phase after experimental stroke models. However, clinical trials
testing this approach failed to show efficacy in stroke patients for the chronic outcome 3 mo after stroke. Here, we identify a
potential mechanistic reason for this phenomenon by detecting chronic T cell accumulation—evading the systemic therapy—in
the post-ischemic brain. We observed a persistent accumulation of T cells in mice and human autopsy samples for more than
1 mo after stroke. Cerebral T cell accumulation in the post-ischemic brain was driven by increased local T cell proliferation
rather than by T cell invasion. This observation urges re-evaluation of current immunotherapeutic approaches, which target
circulating lymphocytes for promoting recovery after stroke.
Introduction
Stroke is one of the leading causes of death and permanent
disability worldwide (World Health Organization, 2017). Despite
the enormousmedical need, specific therapies for stroke patients
are still limited to vascular recanalization approaches within the
acute phase after stroke (Emberson et al., 2014; Fiehler and
Gerloff, 2015; Hacke et al., 2008). In the search for alternative
therapeutic strategies, post-stroke neuroinflammation has come
into focus in current translational stroke research (Iadecola and
Anrather, 2011). Neuroinflammation after stroke is a crucial
pathomechanism contributing to secondary brain injury,
neurodegeneration, and recovery (Iadecola and Anrather,
2011; Moskowitz et al., 2010). While different leukocyte cell
populations have been implicated in the neuroinflammatory
response to stroke, T cells have been consistently shown to be a
key cell population driving secondary brain injury (Chamorro
et al., 2012; Macrez et al., 2011). Consequently, several thera-
peutic strategies targeting the brain invasion of lymphocytes
have been tested using antibodies against key adhesion mole-
cules or by reducing the number of circulating lymphocytes
(Chamorro et al., 2012; Cramer et al., 2019a).
A prominent and controversial example of this translational
approach is the use of anti-CD49d antibodies (Natalizumab),
which reduces the invasion of circulating lymphocytes to the
brain by blocking a key adhesion molecule. The repurposing of
this drug used for patients with multiple sclerosis improved
outcome in the acute phase after experimental stroke in the
majority of preclinical studies (Becker et al., 2001; Langhauser
et al., 2014; Liesz et al., 2011; Neumann et al., 2015; Relton et al.,
2001), which was validated in a first-ever multicenter, ran-
domized preclinical trial (Llovera et al., 2015). In a first phase
2 clinical trial (ACTION), Natalizumab treatment significantly
improved functional outcome (modified Rankin scale) in the
subacute phase (30 d), but this effect was not evident anymore
in the chronic phase (90 d; Elkins et al., 2017). Correspondingly,
a follow-up phase 2b trial (ACTION-II) also did not report any
improvement with Natalizumab treatment in the stroke out-
come at 90 d (Elkind et al., 2020).
Failed translations from promising experimental studies to
clinical trials are commonly attributed to differences in study
design, target engagement, or lack of statistical robustness of the
preclinical findings (Endres et al., 2008; Howells et al., 2014;
Macleod et al., 2014). However, the efficacy of Natalizumab
in preclinical models has been extraordinarily well character-
ized, and clinical trials have closely mimicked the efficient
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therapeutic approaches in animal models in the design of the
treatment regimen and investigated outcome parameters, with
the exception of analyzing different time points after stroke:
Clinical trials analyzed the chronic phase after stroke as the
primary endpoint in contrast to preclinical studies, where only
the acute phase was studied. Therefore, we took a reverse trans-
lational approach and tested whether the design of the clinical
trials—analyzing chronic stroke outcome between patient groups
with similar baseline characteristics after stroke—would have
been efficacious in the murine experimental stroke model.
Confirming a lack of efficacy on chronic post-stroke recovery
also in animal models further prompted us to study the po-
tentially underlying mechanisms of the diverging effects in
acute versus chronic phases after stroke.
Results and discussion
Natalizumab treatment does not improve post-stroke
recovery and neuronal plasticity
To model the clinical study design of Natalizumab treatment for
stroke from the two clinical trials in an animal model, we used a
photothrombotic stroke (PT) model resulting in equal lesion
volumes and behavioral deficits in both treatment groups at the
acute phase, corresponding to the equal characteristics of the
study populations with Natalizumab or control treatment in
the clinical trials. Mice of mixed sex then received anti-CD49d or
an isotype control antibody i.p. 2 h after stroke, followed by
injections every second week over a period of 3 mo, based on
previous reports and the pharmacokinetic analyses of cellular
anti-CD49d saturation (Fig. S1, A–D). We used a panel of in vivo
imaging techniques for cortical plasticity, behavior tests, the
assessment of lesion size and synaptic plasticity, which were
proven to sensitively detect therapeutic effects on chronic post-
stroke recovery (Cramer et al., 2019b; Cserép et al., 2020; Sadler
et al., 2020). Anti-CD49d treatment did not improve long-term
lesion involution based on in vivo widefield imaging (Fig. 1, A
and B; and Fig. S1 D) and also had no effect on histologically
quantified lesion volumes after PT as well as in an independent
stroke model of distal middle cerebral artery occlusion (dMCAo)
used in the majority of previous reports on the effects in the
acute post-stroke phase (Fig. 1 C and Fig. S1 E). Moreover, re-
covery of behavior deficits using a well-established multipa-
rameter neuroscore (Llovera et al., 2015) and cylinder test
(Llovera et al., 2014) also did not differ between treatment
groups throughout the observation period of 3 mo after stroke
(Fig. 1 D). Additionally, we examined functional neuronal con-
nectivity using in vivo widefield calcium imaging. We observed
equal network disturbances in pairwise comparisons of func-
tional cortical areas in both treatment groups after stroke (Fig. 1
E). Moreover, we did not detect anti-CD49d-associated im-
provement in neuronal network connectivity after stroke nei-
ther within the ischemic hemisphere nor across homotopic areas
of both brain hemispheres (Fig. 1 F). Correspondingly, quanti-
fication of synaptic spine density as a marker of synaptic plas-
ticity at 3 mo after stroke did not reveal a difference between
treatment groups, which were both returned to baseline levels
(naive). These results clearly indicate a lack of efficacy for anti-
CD49d to improve functional recovery in the chronic post-stroke
phase in two preclinical stroke models, which is comparable to
the outcome of the clinical trials testing the efficacy of Natali-
zumab in stroke patients (Elkind et al., 2020; Elkins et al., 2017;
Liesz et al., 2011; Llovera et al., 2015).
Anti-CD49d only transiently reduces cerebral lymphocyte
counts after stroke
Therefore, we next aimed to analyze the biological efficacy of
anti-CD49d treatment in reducing long-term lymphocyte inva-
sion to the injured brain, which could not be studied in the
clinical trials. To this end, we performed quantitative flow cy-
tometric analyses at acute and chronic time points after stroke.
Corresponding to previous studies by us and others, anti-CD49d
significantly decreased cerebral lymphocyte invasion at the
acute phase in male and female animals (Fig. 2 A and Fig. S3 A).
In contrast, no difference in cerebral leukocyte count was de-
tectable between treatment groups at 1 mo after stroke for any of
the T cell subtypes, which we quantified in a multidimensional
flow cytometric analysis (Fig. 2, B and C). Interestingly, we
found T cells among leukocyte populations to specifically accu-
mulate in the chronic phase after stroke (Fig. S2). Next, we
performed immunofluorescence labeling of CD3+ T cells to an-
alyze the spatial distribution of T cells after stroke. Consistent
with our flow cytometric results and a previous report (Doyle
et al., 2015), we found dense T cell accumulation within the
chronic lesion but did not detect a difference in intralesional
T cell density between control or anti-CD49d–treated groups at
28 d after stroke (Fig. 2 D). We analyzed the spatial clustering of
T cells by calculating the Clark–Evans agglomeration index (R
index), which indicates cell clustering for an R < 1 (Fig. 2 E).
Interestingly, the R index ranged between 0.3 and 0.7 for both
acute (day 7) as well as for chronic (day 28) time points, re-
gardless of treatment groups. Additionally, chronic T cell accu-
mulation and their local clustering was confirmed in the dMCAo
stroke model for both treatment groups (Fig. S3 B). Thus, the
chronic accumulation of T cells in the post-ischemic brain as-
sociates with local clustering of T cells likely due to local, in-
tracerebral proliferation. This finding could potentially explain
the difference in treatment efficacy of anti-CD49d between the
acute stroke outcome (with transiently reduced cerebral T cell
invasion) and long-term recovery. Taken together, our approach
to monitor the treatment efficacy of anti-CD49d for chronic
recovery in two independent stroke models could have pre-
dicted the inefficacy of Natalizumab in clinical stroke trials.
Moreover, this first-ever analysis of long-term effects of anti-
CD49d treatment on the cerebral lymphocyte pool provides a
mechanistic rationale for the futile treatment effects in the chronic
post-stroke phase.
T cells proliferate intracerebrally after stroke
We next aimed to distinguish chronic recruitment versus local
proliferation as the potential cause of the chronic lymphocyte
accumulation in the post-stroke brain. Therefore, we adminis-
tered 5-ethynyl-29-deoxyuridine (EdU), a thymidine analogue
labeling proliferating cells, in the drinking water over a 7-d time
period, starting either the day of surgery (days 0–7) or 3 wk later
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Figure 1. Longitudinal evaluation of post-stroke recovery in mice receiving anti-CD49d treatment. (A) The lesion area based on autofluorescence after
stroke of individual animals was superimposed to depict the lesion throughout the observation period of 84 d in Thy1-GCaMP6s animals. The color code
indicates the sum of overlapping lesion pixels of individual mice per acquisition time point. Data were generated in two independent experiments. BL, baseline;
D, day. (B) Quantification of the number of autofluorescent pixels seen in calcium imaging of Thy1-GCaMP6s animals. Control (Ctrl): n = 10, anti-CD49d: n = 13,
P = 0.716. Data are shown asmean ± SD, linear-mixed-models, group-by-time interaction. Data were generated in two independent experiments. (C) The lesion
volume was quantified at 7 and 28 d after stroke and shows no difference between treatment groups. Control 7 d: n = 6, control 28 d: n = 11, anti-CD49d 7 d: n = 5,
anti-CD49d 28 d: n = 8, all WT animals. Data are shown as mean ± SD. Ordinary one-way ANOVA + Tukey’s post-hoc test. Data were generated in at least three
independent experiments per time point. (D) Evaluation of the multi-parameter neuroscore and cylinder test shows no difference between treatment groups.
Control: n = 10, anti-CD49d: n = 13, P (neuroscore) = 0.560, P (cylinder) = 0.691. Data are shown as median ± SE, linear-mixed models, group-by-time interaction.
Data were generated in two independent experiments in Thy1-GCaMP6s animals. (E) Illustrative pixelmaps show the group-wise averaged seed-based FC between
eight seeds representing functional cortical areas over an observation period of 84 d after stroke by longitudinal in vivo calcium imaging: 1, left rostral forelimb; 2,
right rostral forelimb; 3, left caudal forelimb; 4, right caudal forelimb; 5, left forelimb sensory area; 6, right forelimb sensory area; 7, left hindlimb sensory area; 8,
right hindlimb sensory area.. Gray squares indicate excluded seed autocorrelation, and white squares indicate excluded seeds due to the stroke lesion, when
excluded in more than three animals. Data are shown as Fisher z-transformed connectivity scores and were generated in two independent experiments in Thy1-
GCaMP6s animals. (F) Schematic illustration for longitudinal in vivo widefield calcium imaging acquisition; left intrahemispheric and whole cortex homotopic FC
Heindl et al. Journal of Experimental Medicine 3 of 11











uenchen user on 27 M
ay 2021
(days 21–28). Then, the rate of proliferating T cells was deter-
mined in blood, spleen, and the ischemic brain hemisphere after
acute (day 7) or chronic (day 28) EdU labeling in untreated mice
(Fig. 3 A). As expected for the acute inflammatory response, we
observed an increase in the proliferation rate (percentage of
EdU+ cells) for cerebral T cells in comparison to splenic and
blood T cells at 7 d after stroke. Surprisingly, the proliferation
rate in the chronic phase was still significantly (more than
twofold) increased for the cerebral T cell population compared
with peripheral organs. In contrast, using systemic antibody
labeling of circulating T cells over 3 d (days 25–28), we detected
only a small number of T cells still de novo–invading the brain in
the chronic phase after stroke (Fig. S3 C). To additionally con-
firm the local proliferation of cerebral T cells, we analyzed
histologically the expression of the direct proliferation marker
Ki67 to quantify the percentage of proliferating T cells within
the chronic stroke lesion (Fig. 3 B). We found independent of the
treatment group a substantial number of >5% Ki67+ T cells,
confirming the local intralesional proliferation of T cells 28 d
after PT (Fig. 3 C), which was also confirmed in the dMCAo
stroke model with comparable findings (Fig. S3 D). These results
suggest that—regardless of anti-CD49d treatment—sustained
and local proliferation of T cells in the post-stroke brain drives
chronic cerebral T cell accumulation after stroke.
Evidence for chronic T cell accumulation in human brain
autopsy samples
To verify chronic T cell accumulation after stroke in brains of
human stroke patients, we obtained 10 individual samples from
two brain banks (Lexington and Debrecen) of six individual
stroke patients dying during the acute and chronic phase after
confirmed cerebral ischemia and excluding other brain dis-
orders or immunological or inflammatory diseases (Table S1).
The area covering the ischemic lesion within the samples was
identified based on H&E staining for quantitative analyses. Us-
ing immunohistochemical staining, we detected CD3+ T cells in
all 10 human brain samples (Fig. 3 D). The number of detected
T cells ranged from ∼300 to >9,000 cells/cm2 of tissue section,
with an average of 80% located within the lesion area. Addi-
tionally, the spatial distribution of T cells within the stroke le-
sions was determined and showed strong local clustering, with
an R index ranging from 0.28 to 0.55 (Fig. 3 E). A Spearman
correlation analysis for T cell density and time since stroke re-
vealed a highly significant positive association. These results
clearly demonstrate that T cells accumulate chronically and
cluster locally in the ischemic lesion of human stroke patients.
We additionally performed immunofluorescence staining for
CD3+ T cells and Ki67 in the most chronically collected patient
sample (124 d after stroke) and detected double-positive cells
(Fig. 3 F), confirming that the phenomenon of local, intracere-
bral proliferation of T cells in the chronic phase after stroke also
applies to human stroke patients.
Taken together, we describe here chronic T cell accumulation
most likely due to local proliferation after ischemic stroke in
mice and human brains, constituting a previously unrecognized
potential confounder for immunotherapeutic studies after is-
chemic stroke. None of the current pharmacological approaches
block completely the cerebral invasion of T cells after stroke (in
contrast to experimental T cell–depletion approaches; Liesz
et al., 2009; Liesz et al., 2011) but rather reduce numbers of
invading T cells by various degrees (Liesz et al., 2011; Llovera
et al., 2015). Therefore, despite the therapeutic intervention,
some T cells invade the ischemic brain. Once in the cerebral
microenvironment, T cells might become autonomous from the
peripheral immune system and establish a tissue-resident pop-
ulation by local proliferation. Here, we confirm chronic T cell
accumulation and local proliferation in two independent ex-
perimental stroke models (PT and dMCAo). However, further
mechanistic studies will be required to explore the biological
function and therapeutic implications of this unexpected
phenomenon.
For this study, wemainly used the PTmodel, which induces a
pronounced cellular neuroinflammatory response and allows for
sensitive analysis of neuromodulatory effects in the chronic
recovery phase after stroke (Cotrina et al., 2017; Sadler et al.,
2020). Key findings on lesion volume, T cell accumulation, and
proliferation have additionally been confirmed in a widely used
dMCAo model with similar findings in male and female animals.
However, considering previous reports on model differences
concerning the extent and dynamics of the neuroinflammatory
response to stroke, future clinical trials need to consider not only
potentially unexpected long-term effects, as reported in this
study, but also potentially drastic differences in the role of
neuroinflammation between stroke subtypes regarding lesion
location, size, and etiology (Cotrina et al., 2017; Cramer et al.,
2019a; Zhou et al., 2013).
As such, our findings have high clinical relevance for many
ongoing or planned immunotherapeutic trials in stroke that
target circulating lymphocytes, their endothelial adhesion, or
cerebral invasion. According to the ClinicalTrials.gov registry of
clinical intervention trials, more than 40 trials are exploring
such strategies with pending outcome as of March 2021. The
therapeutic approaches in these studies cover a broad range of
potential therapies, including (autologous) cell therapies, po-
larization of T cell responses, or modulating lymphocyte mi-
gration. Several of these studies use repurposing of drugs that
of the eight previously defined functional areas. Time course of left intrahemispheric FC (intra FC; P = 0.127) and overall homotopic FC (P = 0.295). Data are
shown as median ± SE, linear-mixed models, group-by-time interaction. Data were generated in two independent experiments in Thy1-GCaMP6s animals.
(G) Representative images of a Golgi-Cox–stained pyramidal neuron layer II/III in a naive animal (scale bar = 30 µm) and 3D reconstruction of pyramidal neuron
dendrites (red) with dendritic spines (blue, scale bar = 5 µm). Dendritic spines were quantified in layer II/III in naive (untreated) animals and 84 d after stroke in
stroke ipsi- and contralateral hemispheres. Naive: n = 5, control: n = 10, anti-CD49d: n = 13. Data are shown as median ± interquartile range. Wilcoxon rank-sum
test with continuity correction and Bonferroni correction for multiple comparisons were used. Data were generated in at least two independent experiments. All
data in this figure were obtained in a mixed-sex cohort (anti-CD49d: four male, nine female; control: three male, seven female), except for C (only male mice).
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have been established and approved for multiple sclerosis, a
disease that not only differs drastically in its pathogenesis but
also has distinct neuroimmunological features. However, the
differences between acute ischemic lesions and chronic auto-
immune brain disorders have not yet been fully characterized
and may pose a threat to the success of immunotherapeutic
stroke trials.
In light of these findings, current clinical trials targeting
lymphocyte migration or brain recruitment (lymphocyte-
depleting antibodies, fingolimod, and cell therapy approaches)
Figure 2. T cells chronically accumulate in the post-ischemic brain independent of anti-CD49d treatment. (A) Flow cytometric quantification of CD4+ T
helper cells and CD8+ cytotoxic T cells per ipsilateral stroke hemisphere at 5 d after stroke. n = 5 per group. Data are shown as mean ± SD, unpaired t test with
Holm–Sidak’s post-hoc test. Data were generated in two independent experiments in WT animals. (B) Quantification of T cell subtypes by multidimensional
flow cytometry 28 d after stroke from the ipsilateral stroke hemisphere was achieved by dimensionality reduction using UMAP (Uniform Manifold Approx-
imation and Projection). The individual clusters were identified as CD3+ T cell subtypes by the MFI of CD8a, CD4, CD62L, CD44, CD69, Foxp3, γδ TCR, and
RORγt, as shown in the heatmap on the right, including activated (act.) CD4+ T helper cells (CD4+CD69+CD62L−), activated CD8+ cytotoxic T cells
(CD8+CD69+CD62L− RORγt+), double-negative T cells (CD4−CD8−), γδ T cells (TCRγδ+CD44+CD69+), naive CD4+ T helper cells (CD4+CD69−CD62L+), naive
CD8+ cytotoxic T cells (CD8+CD69−CD62L+), central memory T cells (TCM; CD8+CD69−CD62L+CD44+), and regulatory T cells (Treg; CD4+FOXP3+).
(C)Quantification of numbers of T cell subtypes per cluster in the ipsilateral stroke hemisphere shown in B. Control: n = 5, anti-CD49d: n = 7. Data are shown as
mean ± SD; unpaired t test and Holm–Sidak post-hoc test. The data were generated in three independent experiments in WT animals. (D) Representative
immunofluorescence images of CD3+ T cells in the brain 28 d after stroke of the whole section with demarcation of the lesion (upper left, scale bar = 1 mm), the
lesion area (lower left, scale bar = 500 µm), and an area within the lesion from control and anti-CD49d animals (right, scale bars = 30 µm). The T cell density
within the lesion (cells per square millimeter) showed no difference between groups. Control: n = 11, anti-CD49d: n = 8. Data are shown as mean ± SD; unpaired
t test. The data were generated in at least three independent experiments in WT animals. (E) Schematic representation of the R index for describing cell
clustering (left) and the R index for CD3+ T cells within the lesion at 7 and 28 d after stroke for both treatment groups (right). Control 7 d: n = 6, control 28 d:
n = 11, anti-CD49d 7 d: n = 5, anti-CD49d 28 d: n = 8. Data are shown as median ± interquartile range. *, P < 0.05; #, P (clustered [R < 1]) <0.0001; ordinary one-
way ANOVA + Tukey’s post-hoc test. Data were generated in at least three independent experiments per time point in WT animals.
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need to be fundamentally reconsidered. Mechanisms of chronic
neuroinflammation after stroke and the consequences for post-
stroke recovery need to be better understood for the rationale
design of efficient immunotherapies in stroke.
Materials and methods
Animals
All experiments in this studywere conducted in accordancewith
the national guidelines for animal experiments and approved
by the German governmental committees (Regierungpraesidium
Oberbayern, Munich, Germany). For flow cytometric and im-
munohistochemical analyses, the animals were 8–12-wk-oldmale
or female C57BL/6J mice (Charles River Laboratories). For in vivo
widefield calcium imaging and dendritic Golgi spine analysis,
the animals were 12–15-wk-old male and female C57BL/6J-
Tg(Thy1-GCaMP6s)GP4.12Dkim/J (here termed Thy1-GCaMP6s;
Dana et al., 2014) heterozygous mice bred at the Institute for
Stroke and Dementia Research, Munich (>12 generations back-
crossed on C57Bl6/J WT mice). The animals were housed under
controlled temperature (22 ± 2°C) with a 12-h light/dark cycle
and access to food and water ad libitum. All animal experiments
were performed and reported in accordance with the ARRIVE
guidelines (Kilkenny et al., 2010).
Stroke surgery
For PT induction, mice were anaesthetized with isoflurane, de-
livered in a mixture of 30% O2 and 70% N2O. Mice were placed
Figure 3. T cells chronically proliferate in the postischemic brain in mice and stroke patients. (A) The percentage of EdU+ T cells was quantified by flow
cytometry in the spleen, blood, and ipsilateral stroke hemisphere at day 7 and day 28 after stroke (n = 5 per group). Data are shown as mean ± SD; ordinary
one-way ANOVA and Tukey’s post-hoc test. Two independent experiments per time point were performed in WT animals. (B) Representative images show
immunofluorescence staining for CD3 and Ki67 within the lesion area for the detection of intracerebral T cell proliferation 28 d after stroke in both treatment
groups (upper row, control; lower row, anti-CD49d). Arrows point to CD3 and Ki67 double-positive T cells. Scale bars = 10 µm. (C) Quantification of the
percentage of Ki67+ T cells from (B) within the lesion 28 d after stroke showed no difference between the treatment groups. control: n = 11, anti-CD49d: n = 8.
Data are shown as mean ± SD. Unpaired t test. The data were generated in at least three independent experiments in WT animals. (D) Representative images
are shown for CD3+ DAB staining on consecutive brain sections from a human sample (124 d since stroke onset). Higher magnification images are shown from
respective indicated areas. Scale bars: left, 1 mm; middle, 400 µm; right, 10 µm. (E) Cell density (cells/square centimeter) of intra- and extralesional CD3 T cells
and cell clustering by R index were quantified. P (clustered [R < 1] <0.0001) for all analyzed samples. Correlation analysis (Spearman) between T cell density
and time since stroke onset per sample. (F) Representative images of immunofluorescence staining for CD3 and Ki67 within the previously histopathologically
identified lesion area are shown for the patient samples with the highest detected T cell count (124 d since stroke onset). Arrows point to CD3 and Ki67 double-
positive T cells. Scale bar = 10 µm. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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into a stereotactic frame, and body temperature was maintained
at 37°C with a mouse warming pad. Dexpanthenol eye ointment
was applied to both eyes. Animals received 10 µl/g body weight
of 1% Rose Bengal (198250-5g; Sigma-Aldrich) in saline i.p. 5 min
before the induction of anesthesia (5% isoflurane). A skin inci-
sion was used to expose the skull. Bregma was located, and the
lesion location was marked in the left hemisphere (1.5 mm lat-
eral and 1.0mm rostral to bregma). For in vivowidefield calcium
imaging experiments, PT was induced as previously described
(Cramer et al., 2019b). In brief, an independent vector analysis
was performed based on baseline resting-state imaging, which
allowed us to define cortical functional regions as independent
components. The independent component in the primary motor
cortex was then used to individually define the lesion location
for every mouse. Shielding was placed on the skull, allowing a
2.0-mm-diameter circular light exposure over the lesion area.
10 min after Rose Bengal injection, the laser (25 mV output) was
applied to the lesion area for 17 min (Cobolt Jive 50, 561 nm
power at 25mV; Fiber Collimation Package: 543 nm, f = 7.66mm,
beam diameter [d] ≈ (4)(0.000561 mm)[7.86 mm/(pi × 0.004
mm)] = 1.4 mm). The sham procedure was performed as de-
scribed previously but without laser illumination.
dMCAo was performed as previously described (Llovera
et al., 2014). Briefly, the mouse was positioned on its side and
skin was incised between the ear and the eye. After, the tem-
poral muscle was detached from the bone and a craniotomy was
performed on top of the middle cerebral artery. The vessel was
permanently coagulated, proximal and distal to the MCA bi-
furcation, with electrocoagulation forceps. Finally, the muscle
was placed back and the wound sutured.
Anti-CD49d antibody treatment
Animals were treated with 300 µg anti-CD49d (clone PS/2,
catalog no. BE0071; Bio X Cell) or isotype control (LTF-2, catalog
no. BE0090; Bio X Cell) in 0.01 M PBS 2 h after PT induction,
followed by injection every second week until termination of
the experiment. The treatment groups were assigned after
randomization, and experimenters were blinded to group
assignment.
Neuroscore
The multiparametric neuroscore was assessed as previously
described (Orsini et al., 2012). Briefly, the score is composed of
the assessment of several subtests of both global and focal def-
icits. Assessment of global deficits included grooming, status of
ears and eyes, posture, spontaneous activity, and epileptic be-
havior. Focal deficits were evaluated by gait, grip, forelimb
asymmetry during tail suspension, circling behavior of the en-
tire body or only a forelimb, body symmetry, and whisker re-
sponse. Total score ranges from 0 to 54 points (26 points for
general and 28 for focal deficits), with a higher score indicating
worse deficits. Data were acquired once before stroke and on
days 3, 7, 14, 21, 28, 42, 56, 70, and 84 after stroke.
Cylinder test
The cylinder test was assessed as previously described (Llovera
et al., 2014). Briefly, the animals were placed in a transparent
acrylic glass cylinder (diameter, 8 cm; height, 25 cm) in front of
two mirrors, and video was recorded for 10 min. The frequency
of forelimb use during a full rear and landing with only one
forelimbwas counted. At least 20 contacts for one forelimbwere
counted using slow-motion or frame-by-frame function. The
ratio was calculated as the total number of left forelimb contacts
divided by the total number of right forelimb contacts with the
cylinder wall.
Flow cytometry
Mice were deeply anesthetized and perfused with 20 ml saline.
Both brain and spleen were dissected, and blood was collected in
EDTA tubes after cardiac puncture. For brain, both hemispheres
were carefully removed, and cells were isolated by mechanical
dissociation. Cell preparation and staining were performed as
previously described (Llovera et al., 2017). Mononuclear cells
were enriched using discontinuous Percoll gradients. Cell stain-
ings were performed using the following antibodies: CD45-eF450
(1:250, 48–0451-82, clone: 30-F11; Invitrogen), CD3-FITC (1:250,
11–0032-82, clone: 17A2; Invitrogen), CD8-PE (1:250, 12–0081-82,
clone: 53–6.7; Invitrogen), CD4-PerCP-Cy5 (1:250, 45–0042-82, clone:
RM4-5; Invitrogen), TCRyd-APC (1:250, 118116, clone: GL3;
BioLegend), NK1.1-PE-Cy7 (1:250, 25–5941-82, clone: PK136; In-
vitrogen), CD19-APC-Cy7 (1:250, 47–0193-82, clone: eBio1D3; In-
vitrogen), CD11b-PerCP-Cy5 (1:250, 45–0112-82, clone: M1/70;
Invitrogen), MHCII-PE (1:250, 12–5322-81, clone: NIMR-4; eBio-
science), Ly6C-APC (1:500, 17–5932-82, clone: HK1.4; eBioscience),
Ly6G-PE-Cy7 (1:333, 25–5931-82, clone: RB6-8C5; eBioscience), and
CD11c-APC-Cy7 (1:250, 117324, clone: N418; BioLegend). Stained
cells were analyzed on a BD FACSVerse flow cytometer (BD Bio-
sciences), and analysis was performed using FlowJo software
(version 10.0).
For high-dimensional flow cytometry (Fig. 2, B and C), mice
were injected i.v. with 3 µg CD45-APC-Cy7 (103116, clone: 30-F11;
BioLegend), 3 min before transcardiac perfusion, to exclude
blood contamination. Mononuclear cells were then isolated as
described above. The samples were stained first with Zombie
NIR Fixable Viability Kit (1:200; BioLegend) and surface mark-
ers, diluted in Brilliant Stain Buffer (BD Biosciences). The fol-
lowing antibodies were used: CXCR3-BV421 (1:100, 126522, clone:
CXCR3-127; BioLegend), CD27-SB436 (1:100, 62–0271-82, clone:
LG.7F9; eBioscience), CD69-BV480 (1:50, 746813, clone: H1.2F3; BD
Biosciences), CD19-BV570 (1:200, 115535, clone: 6D5; BioLegend),
CD11b-BV570 (1:200, 101233, clone: M1/70; BioLegend), PD-1-
BV605 (1:100, 563059, clone: J43; BD Biosciences), CD62L-BV650
(1:100, 564108, clone MEL-14; BD Biosciences), TCR-γδ-BV750
(1:100, 746962, clone: GL3; BD Biosciences), CCR7-BV785 (1:100,
120127, clone: 4B12; BioLegend), CD44-AF532 (1:200, 58–0441-82,
clone: IM7; eBioscience), CD127-PE-CF594 (1:100, 562419, clone:
SB/199; BD Biosciences), NK1.1-AF700 (1:100, 56–5941-82, clone:
PK136; eBioscience), CD8a-BV510 (1:200, 563068, clone: 53-6.7; BD
Biosciences), CD3-FITC (1:200, 11–0032-82, clone: 17A2; eBioscience),
KLRG1-PE (1:200, 138408, clone: 2F1/KLRG1; BioLegend), CD103-PE-
Cy7 (1:200, 121426, clone: 2E7; BioLegend), CD4-PerCP-Cy5.5 (1:200,
45–0042-82, clone: RM4-5; eBioscience). For intracellular staining,
Foxp3 / Transcription Factor Staining Buffer Set was used
following the provider guidelines. The following antibodies
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for intracellular staining were used: FoxP3-AF647 (1:100,
126408, clone: MF-14; BioLegend), T-bet-BV711 (1:100, 644820,
clone: 4B10; BioLegend), ROR-γt-APC (1:100, 17–6981-82, clone
B2D; eBioscience). Stained cells were analyzed on a Norther
Light spectral flow cytometer (Cytek) and analysis performed
by FlowJo software (version 10.0).
In vivo proliferation analysis
For analysis of in vivo cell proliferation, mice were treated with
EdU (0.5mg/ml; Invitrogen) in sucrose-enriched drinkingwater
(5 g sucrose in 100 ml) for 7 d before saline perfusion. EdU was
detected using a Click-iT EdU Alexa Fluor 647 Flow Cytometry
Assay Kit (C10419; Invitrogen) following the manufacturer’s
instructions. Subsequently, FACS antibody staining was per-
formed as described above using the following cell surface
antibodies: CD11b-PE-Cy7 (1:250, 25–0112-82, clone: M1/70;
Invitrogen), CD45-BV510 (1:250, 563891, clone: 30-F11; BD
Biosciences), CD3-FITC (1:250, 11–0032-82, clone: 17A2; In-
vitrogen), CD19-eF450 (1:250, 48–0193-82, clone: eBio1D3;
eBioscience), CD4-PerCP-Cy5.5 (1:250, 45–0042-82, clone: RM4-
5; Invitrogen), and CD8-PE (1:250, Invitrogen, 12–0081-82, clone:
53–6.7). Stained cells were then analyzed on a BD FACSVerse
flow cytometer (BD Biosciences), and analysis was performed
using FlowJo software (version 10.0).
Pharmacokinetic analysis
To determine cellular anti-CD49d saturation levels, venous
blood was collected in EDTA tubes after cardiac puncture, and
mononuclear cells were enriched using a Histopaque-1077 gra-
dient (Sigma-Aldrich). Cells were diluted to a concentration of
106 cells/ml and stained with a mouse anti-Rat IgG2b PE-
conjugated secondary antibody (1:20, clone R2B-7C3; eBio-
science) to detect cell-bound anti-CD49d for 30 min at 4°C. For
determination of anti-CD49d saturation, cells were incubated
with a saturating amount of anti-CD49d (10 µg/ml) for 30min at
room temperature and subsequently stained with the antibody
as described above. Stained cells were then analyzed on a BD
FACSVerse flow cytometer (BD Biosciences), and analysis was
performed using FlowJo software (version 10.0). The anti-CD49d
saturation level was then calculated as percentage of the mean
fluorescence intensity (MFI) from in vivo bound anti-CD49d
from the MFI of in vitro saturated cells by the following
equation:
anti − CD49d saturation 
MFI in vivo bound anti − CD49d
MFI in vitro saturated anti − CD49d × 100.
The number of anti-CD49d molecules per cell was determined
using a PE fluorescence quantitation kit (BD Quantibrite
PE, #340495; BD Biosciences) following the manufacturer’s
instructions.
Mouse anti-rat IgG ELISA
To analyze neutralizing mouse anti-rat IgG antibodies in mice,
we used a customized modification of a commercial ELISA (#88-
50400; Thermo Fisher Scientific). Flat-bottom 96-well ELISA
plates were coated overnight with the same rat anti-CD49d
antibody (100 ng/ml) at 4°C as used for the in vivo treatment
(clone PS/2, Cat. BE0071; Bio X Cell). After washing, the
antibody-coated plates were incubated for 1 h at room temper-
ature with mouse plasma obtained 28 d after stroke (i.e., two
doses of anti-CD49d at 2 h and 14 d) or control plasma from a
naive mouse that had been spiked at ∼10 ng/ml with the capture
antibody of the ELISA kit. Subsequent detection and bio-
chemiluminescent analysis using a microplate reader (Bio-Rad)
was performed following the manufacturer’s instructions.
Dendritic spine analysis
Following saline perfusion, mice were perfused 84 d after PT
with aldehyde fixative solution (003780; Bioenno). Brains were
then carefully removed and placed in fixative solution at 4°C
overnight. Brains were then sliced at 100 µm using a vibratome
and collected in 0.1 M PBS. Slices were placed in impregnation
slice Golgi Kit (003760; Bioenno) solution for 5 d in the dark.
Staining and post-staining was performed as described by the
manufacturer (Bioenno). Images of dendrites were obtained
within 500 µm around the lesion area in cortical layer 2/3. In
total, 25 dendrites per animal (5 dendrites from 5 neurons) in
both hemispheres were recorded using an Axio Imager.M2 and a
100× objective (EC Plan-Neofluar, numerical aperture [NA] =
1.3, oil immersion, acquisition at 18–20°C) using the AxioCam
MRc and AxioVision 4.8.2 software. Dendrites from the images
were then 3D reconstructed and the spine density evaluated on
the reconstructed 3D surface using Imaris x64 (8.4.0; Bitplane).
In vivo widefield neuronal calcium imaging
In vivo widefield calcium imaging was performed as previously
published (Cramer et al., 2019b). Briefly, Thy1-GCaMP6s heter-
ozygous mice were scalped and transparent dental cement was
placed upon the intact skull at least 3 d before start of the ex-
periment. Resting-state in vivo imaging was performed in mild
anesthesia (0.5 mg/kg body weight of medetomidine with 0.75%
isoflurane inhalation). Mice were placed in a stereotactic frame
below a customized macroscopic imaging setup, and mouse
cortex was illuminated with 450-nm blue LED light. Resting-
state calcium activity was recorded for 4 min (6 × 1,000
frames) with a high-precision 2/3” Interline charge-coupled
device camera (Adimec-1000m/D, pixel size 7.4 × 7.4 µm, ac-
quisition at 20–22°C; Adimec) at a 25-Hz frame rate using
longDaq software (Optical Imaging).
In vivo calcium imaging analysis
Functional imaging data were preprocessed as previously de-
scribed (Cramer et al., 2019b). In particular, the seed-to-seed FCs
between eight previously defined seeds were calculated as
Pearson’s correlation between the time course of each of these
seeds and Fisher’s z transformation. For left intrahemispheric
connectivity, the mean of the Fisher’s z-transformed Pearson’s
correlation coefficient of each connection between the seeds
located in the left hemisphere was calculated. The overall ho-
motopic connectivity was calculated as the mean of all Fisher’s
z-transformed Pearson’s correlation coefficients of each homo-
topic connection between the seeds in both hemispheres. The
time course of left intrahemispheric and overall homotopic
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connectivity was displayed from baseline and days 42 to 84 after
stroke, ensuring the visibility of all seeds after disappearance
of the autofluorescent lesion. Fisher’s z-transformed Pearson’s
correlation was calculated using MATLAB (MathWorks R2016b
with Optimization Toolbox, Statistics and Machine Learning
Toolbox, Signal Processing Toolbox and Image Processing
Toolbox; MathWorks).
Lesion involution quantification
The lesion size was determined by autofluorescence of the
ischemic tissue in Thy1-GCaMP6s animals used for in vivo
widefield calcium imaging for every time point of imaging
acquisition. The area of autofluorescent pixels was previously
defined by thresholding and converted into a mask to exclude
autofluorescent tissue from the connectivity analysis. The lesion
was determined as the size of the exclusion mask by quantifi-
cation of all pixels within the mask.
Lesion volumetry
Mice were transcardially perfused 28 d after PT or dMCAo
stroke induction with saline and 4% paraformaldehyde solution.
To protect the cortical lesion from damage, the whole skull was
isolated and stored in 4% paraformaldehyde overnight at 4°C and
then placed in 0.3 M EDTA for 7 d for decalcification. Subse-
quently, the brains were dehydrated for 2 d in 30% sucrose in
0.01 M PBS and then snap-frozen in isopentane. Cresyl Violet
staining for infarct volumetry was performed as previously
described (Llovera et al., 2014), and the lesion size was quanti-
fied using FIJI ImageJ.
Immunohistochemical staining of mouse coronal
brain sections
Fluorescent immunohistochemical staining for CD3+ and Ki67+
to determine the number of proliferating T cells in control
versus anti-CD49d treated animals was performed on 20-µm-
thick paraformaldehyde-fixed coronal sections from mice at 7
and/or 28 d after PT or dMCAo. Sections were fixed with cold
acetone for 10min at room temperature andwashedwith 0.01M
PBS before blocking with goat serum blocking buffer for 1 h at
room temperature. Subsequently, sections were stained over-
night at 4°C with primary antibody (1:200, CD3e, hamster anti-
mouse, clone 500A2; BD PharMingen; and 1:200, Ki-67, rabbit
mAb, clone D3B5; Cell Signaling Technology). After washing with
0.1% Triton X-100 in 0.01M PBS, secondary antibody staining was
applied for 2 h at room temperature (1:200, goat anti-hamster,
Alexa Fluor 594; Thermo Fisher Scientific; and 1:200, goat anti-
rabbit, Alexa Fluor 647; Life Technologies). Nuclei were stained
with DAPI (1:5,000; Invitrogen) for 5 min at room temperature.
Per animal, three images for cell quantification were re-
corded as 6-µm-high tile-scan Z-stacks (slice thickness, 0.4 µm)
on a Zeiss confocal microscope (LSM880) with 25× objective
(LCI Plan-Neofluar 25×, NA = 0.8, ImmKorr differential inter-
ference contrast, water immersion, acquisition at 18°C). The
lesion was marked andmeasured in the tile-scan image and cells
were quantified using the Cell Counter Plugin in FIJI. Cell den-
sity was calculated as number of cells per squaremillimeter. The
R index for quantification of clustering of cells per area was
calculated using the clarkevans.test R function (R package
spatstat; Baddeley et al., 2005). For evaluation of clustering, the
ratio of the observed average nearest-neighbor distance r (rA) to
the expected pattern for a Poisson point process of the same
intensity (rE): R=rArE. An R index of >1.0 indicates ordered spatial
distribution, R = 0 indicates even distribution, and R < 1.0 in-
dicates aggregation. Hypothesis testing was performed against
the null hypothesis, which is complete spatial randomness/a
uniform Poisson process. For every animal, the cell density and
R index were calculated and averaged among the three acquired
images. Whole-slice images were acquired using a 10× objective
(EC Plan-Neofluar 10×, NA = 0.3, air immersion, acquisition at
18°C) and high-resolution images were acquired using a 40×
objective (EC Plan-Neofluar 40×, NA = 1.3 oil differential inter-
ference contrast, oil immersion, acquisition at 18–20°C).
Patient characteristics for postmortem histological analyses
Ethical approval for the use of human postmortem material was
granted according to institutional ethics board protocol and
national regulations by the HungarianMedical Research Council
Scientific and Research Ethics Board (19312/2016/EKU) and the
University of Kentucky Medical Institutional Review Board (UK
IRB #44009), respectively. Clinical information was provided by
the respective brain bank (Table S1).
Histological and immunohistochemical staining of human
brain tissue samples
Histochemical and immunohistochemical staining was per-
formed on sections cut to 6 µm from paraffin-embedded tissue
blocks. Randomly chosen sections of every patient were depar-
affinated and rehydrated and subsequently stained with H&E.
Immunohistochemistry for CD3 (polyclonal rabbit anti-human
CD3, diluted 1:50, A0452; Dako) was performed on sections ad-
jacent to H&E-stained sections with the Ventana Benchmark GX
automated staining system using a CC1 (Roche) pretreatment
and the iView DAB Detection Kit (Roche). Sections were coun-
terstained with hematoxylin and coverslipped with Entellan
(Merck) as mounting medium. Age of infarcts was estimated by
two experienced and independent neuropathologists (T. Arzberger
and P.T. Nelson) on H&E sections according to published criteria
(Mena et al., 2004). CD3 stains were scanned with Zeiss Axio
Scan Z1 using a 20× objective. The infarct area was demarcated,
and the absolute numbers and coordinates of intra- and extra-
lesional CD3+ T cells were assessed manually using Qupath
(version 0.2.2). Cell density was calculated as number of cells per
cm2 of defined lesion area. The R index for quantification of cell
clustering per area was calculated as described above in R (ver-
sion 3.6.0). Intralesional cell density was correlated with time
after stroke onset for each sample.
Immunofluorescence staining of human brain tissue samples
Immunofluorescence staining was performed on sections cut to
6 µm from paraffin-embedded tissue blocks. Randomly selected
sections were deparaffinated and blocked in 3% H2O2. After
heat-induced antigen retrieval in Tris-buffered EDTA (pH 9.0)
for 30min at 95°C, sections were blocked with 5% donkey serum
for 4 h at room temperature. Then, sections were incubated in
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antibody staining solution (0.3% Triton X-100 and 20 mM so-
dium azide containing 0.05 M Tris-buffered saline [TBS], pH
7.4) overnight at 4°C (1:50, CD3, polyclonal rabbit anti-human,
reference A0452; and 1:100, Ki67, monoclonal mouse anti-
human, clone MIB-1, reference M7240; Dako). After washing
with 0.05 M TBS, secondary antibody staining was performed
with antibody staining solution (0.3% Triton X-100 and 20 mM
sodium azide containing 0.05 M TBS, pH 7.4) for 2.5 h at room
temperature in the dark (1:500, donkey anti-rabbit, Alexa Fluor 594,
reference 711–586-152; and 1:500, donkey anti-mouse, Alexa Fluor
488, reference 715–546-151; Jackson ImmunoResearch). For nuclear
staining, Hoechst 33334 (0.02mg/ml diluted in 0.05MTBS, pH 7.4,
reference 62249; Thermo Fisher Scientific) was applied for 30 min
at room temperature. After staining, an autofluorescence elimi-
nator reagent (reference 2160; EMD Millipore) was applied for
5 min before mounting the slides with Fluoromount-G (reference
0100–01; Southern Biotech). The images were acquired at 20×
magnification (objective: Plan Apo VC 20×, NA = 0.75, working
distance = 1 mm, field of view = 645.12 µm, calibration: 0.62 µm/
pixel orwith 5× optical zoom, calibration: 0.12 µm/pixel, acquisition
at 21°C) using a Nikon Ni C2 confocal microscope.
Statistics
To assess whether the lesion involution (number of auto-
fluorescent pixels), behavioral recovery (neuroscore and cylin-
der test) or FC (left intra-FC and overall homotopic FC) between
anti-CD49d–treated and control-treated animals were signifi-
cantly different, we performed linear-mixed models for cal-
culating group-by-time interaction in R (version 3.6.0). To test
for statistical difference in infarct volume between treatment
groups, we used one-way ANOVA and Tukey’s post-hoc test.
Next, we assessed the difference in dendritic spine numbers
between anti-CD49d–treated and control-treated animals using
the Wilcoxon rank-sum test with continuity correction and
Bonferroni post-hoc correction for multiple testing in R (Version
3.6.0). To test for significantly different numbers of infiltrating
T cells between anti-CD49d– and control-treated animals, we
used unpaired t tests and Holm–Sidak’s correction for multiple
testing. For determining significant differences in histologically
quantified T cells, we used an unpaired t test. To assess signif-
icant differences in the R index between treatment groups at
different time points, we used one-way ANOVA and Tukey’s test
for correction of multiple comparisons. We next quantified
significant differences between the number of EdU+ T cells in
different organs using one-way ANOVA and Tukey’s test for
correction of multiple comparisons. To test for significant dif-
ferences in the percentage of Ki67+ T cells between treatment
groups, we used an unpaired t test. We used linear regression
analysis to test for a correlation between the intralesional T cell
density in stroke patients and time after stroke onset. Unless
otherwise mentioned all analyses were performed in GraphPad
Prism (version 7.0a). For all analyses, an α level of adjusted P <
0.05 was considered statistically significant.
Online supplemental material
Fig. S1 provides pharmacokinetic analysis data for the rationale
of the treatment regimen with anti-CD49d and additional results
on infarct volumetry supporting the findings in the Fig. 1 in the
PT and dMCAo stroke model. Fig. S2 provides information on
the temporal dynamics of cerebral invasion on innate and
adaptive immune subpopulations over 1 mo after experimental
stroke. Fig. S3 shows comparable findings for chronic T cell
accumulation in female mice as shown in the main figures for
male mice. Additionally, this figure confirms chronic T cell ac-
cumulation and proliferation in the dMCAo stroke model. Table
S1 lists patient data.
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Supplemental material
Figure S1. Rationale for anti-CD49d treatment regimen and infarct volumetric assessment. (A) Flow cytometric analysis of acute CD4+ and CD8+ T cell
infiltration into the ipsilateral hemisphere after photothrombosis; n (0 = sham) = 10, n (2 h) = 3, n (3 d) = 6, n (7 d) = 6, n (14 d) = 5. Data are shown asmean + SD;
ordinary one-way ANOVA + Dunnett’s post-hoc test. At least two independent experiments were performed per time point inWT animals. (B) Saturation levels
of anti-CD49d measured at 2 h and 7 and 14 d after i.p. injection of 300 µg anti-CD49d per animal; n = 3–4 per time point. Data are shown as mean + SD. Data
were acquired in at least two independent experiments in WT animals. (C) Quantification of anti-CD49d molecules bound per cell at 2 h and 7 and 14 d after
anti-CD49d treatment; n = 3–4 per time point. Data were acquired in at least two independent experiments in WT animals. (D)Mouse plasma concentration of
anti-rat IgG is shown at day 28 from mice receiving two injections of 300 µg anti-CD49d at 2 h and 14 d after stroke. Naive mouse plasma was spiked with
monoclonal anti-rat IgG as a positive control (spiked plasma); n = 3. (E) Correlation of lesion volume (histological analysis) and lesion size (autofluorescent
pixels). Pearson correlation n = 13. Data were acquired in two independent experiments in Thy1GCaMP6s animals. (F) Infarct volume 28 d after distal middle
cerebral occlusion; n (control) = 6, n (αCD49d) = 5. Data are shown as mean + SD. Unpaired t test. Data were acquired in three independent experiments in WT
animals. **, P < 0.01; ***, P < 0.001.
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Figure S2. Temporal dynamics of myeloid and lymphoid immune cell infiltration after stroke. (A–F) Absolute counts of monocytes (A), activated
monocytes (B), neutrophils (C), CD4+ T helper cells (D), CD8+ cytotoxic T cells (E), and CD19+ B cells (F) were assessed using flow cytometry at 2 h and 3–28 d
after stroke, as well as after sham surgery (day 0) in the ipsilateral hemisphere; n (sham) = 10, n (2 h) = 3, n (3 d) = 5–6, n (7 d) = 5–6, n (14 d) = 5, n (28 d) = 5.
Mean values are shown per time point. Ordinary one-way ANOVA + Dunnett’s post-hoc test. At least two independent experiments were performed per time
point in WT animals. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Heindl et al. Journal of Experimental Medicine S2
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Table S1 is provided online as a Word document and lists patient data.
Figure S3. Chronic T cell accumulation in female mice and after dMCAo. (A) Flow cytometric analysis of CD4+ and CD8+ T cells 28 d after stroke in female
mice; n = 7–8 per group, unpaired t test. Data are shown as mean + SD. (B) Evaluation of cell density and cell agglomeration of CD3+ intralesional T cells 28 d
after dMCAo; n = 5 per group, unpaired t test. Data are shown as mean + SD/median and interquartile range. (C) i.v. labeling of circulating CD45+ leukocytes
over 3 d before flow cytometric brain analysis 28 d after stroke reveals only a small fraction of brain-invading CD4+ and CD8+ T cells out of total cerebral T cells
in the ischemic hemisphere; n = 4. Data are shown as mean + SD. (D) Percentage of Ki67+ T cells 28 d after dMCAo; n = 5 per group, unpaired t test. Data are
shown as mean + SD. All data were generated in three independent experiments in WT animals. #, P < 0.05 for R < 1.0.
Heindl et al. Journal of Experimental Medicine S3
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